Neumora Therapeutics is trading 10.35% down at $0.90 after broader biotech weakness intensified following disappointing clinical-trial news from Ionis Pharmaceuticals.
- No new company-specific announcement was identified for September 15, 2026.
- The decline extends a multiday slide after earlier navacaprant Phase 3 failures and workforce reduction, which remain important background risks but are not a fresh catalyst today.